Biohaven Ltd. Investing Cash Flow
Biohaven Ltd. (BHVN) reported Investing Cash Flow of $60.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-10
- Biohaven Ltd. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $44.82M.
- Biohaven Ltd. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $15.21M, a 90.77% decline year-over-year.
- Biohaven Ltd. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$13.74M.
- Biohaven Ltd. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $164.97M.
- Biohaven Ltd. net cash provided by (used in) investing activities for fiscal 2025 was $300.56M.
- Biohaven Ltd. net cash provided by (used in) investing activities for fiscal 2024 was -$244.97M, a 288.69% decline from fiscal 2023.
- Biohaven Ltd. net cash provided by (used in) investing activities for fiscal 2023 was $129.83M.
- Biohaven Ltd. net cash provided by (used in) investing activities for fiscal 2022 was -$304.79M, a 32387.08% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $60.03M 10-Q · filed 2026-08-10 | $46.30M derived: sum of 3 quarters · filed 2026-08-10 | $211.26M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $15.21M 10-Q · filed 2026-05-04 | $1.47M derived: sum of 2 quarters · filed 2026-05-04 | $166.44M derived: sum of 3 quarters · filed 2026-05-04 | $150.89M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $151.23M derived: sum of 2 quarters · filed 2026-03-02 | $135.68M derived: sum of 3 quarters · filed 2026-08-10 | $300.56M 10-K · filed 2026-03-02 |
| 2025-09-30 | $164.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $149.42M derived: sum of 2 quarters · filed 2026-08-10 | $314.30M 10-Q · filed 2025-11-10 | $226.62M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$15.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $149.33M 10-Q · filed 2026-08-10 | $61.66M derived: sum of 3 quarters · filed 2026-08-10 | -$31.74M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $164.88M 10-Q · filed 2026-05-04 | $77.20M derived: sum of 2 quarters · filed 2026-05-04 | -$16.20M derived: sum of 3 quarters · filed 2026-05-04 | -$114.13M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$87.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$181.07M derived: sum of 2 quarters · filed 2026-03-02 | -$279.00M derived: sum of 3 quarters · filed 2026-03-02 | -$244.97M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$93.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$191.33M derived: sum of 2 quarters · filed 2025-11-10 | -$157.30M 10-Q · filed 2025-11-10 | -$161.21M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$97.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$63.90M 10-Q · filed 2025-08-11 | -$67.81M derived: sum of 3 quarters · filed 2026-03-02 | -$9.27M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $34.03M 10-Q · filed 2025-05-12 | $30.12M derived: sum of 2 quarters · filed 2026-03-02 | $88.67M derived: sum of 3 quarters · filed 2026-03-02 | $164.92M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $54.63M derived: sum of 2 quarters · filed 2026-03-02 | $130.89M derived: sum of 3 quarters · filed 2026-03-02 | $129.83M 10-K · filed 2026-03-02 |
| 2023-09-30 | $58.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $134.80M derived: sum of 2 quarters · filed 2024-11-12 | $133.74M 10-Q · filed 2024-11-12 | -$130.27M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $76.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $75.19M 10-Q · filed 2024-08-09 | -$188.82M derived: sum of 3 quarters · filed 2025-03-03 | -$193.34M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$1.06M 10-Q · filed 2024-05-09 | -$265.07M derived: sum of 2 quarters · filed 2025-03-03 | -$269.60M derived: sum of 3 quarters · filed 2025-03-03 | -$305.60M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$264.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$268.54M derived: sum of 2 quarters · filed 2025-03-03 | -$304.54M derived: sum of 3 quarters · filed 2025-03-03 | -$304.79M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$4.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$40.53M derived: sum of 2 quarters · filed 2023-11-14 | -$40.77M 10-Q · filed 2023-11-14 | -$40.98M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$36.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | -$36.25M 10-Q · filed 2023-07-31 | -$36.45M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2022-03-31 | -$246.00K 10-Q · filed 2023-05-12 | -$447.00K derived: sum of 2 quarters · filed 2024-02-29 | ||
| 2021-12-31 | -$201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $944.00K 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $1.15M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | -$2.70M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |